Quick Answer
Kura Oncology, Inc. reported Cash and Equivalents of $149.10 million for fiscal year 2025.
Kura Oncology, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $149.10M | -33.6% |
| 2024 | $224.46M | +501.5% |
| 2023 | $37.32M | -28.0% |
| 2022 | $51.80M | -42.9% |
| 2021 | $90.67M | -72.1% |
| 2020 | $325.49M | +1145.4% |
| 2019 | $26.14M | +62.1% |
| 2018 | $16.12M | +41.0% |
| 2017 | $11.43M | +17.6% |
| 2016 | $9.72M | -37.0% |
| 2015 | $15.44M | +1273.9% |
| 2014 | $1.12M | +17013.3% |
| 2013 | $6.6K | +36.8% |
| 2012 | $4.8K | -14.0% |
| 2012 | $5.6K | +32.4% |
| 2011 | $4.2K | -31.4% |
| 2011 | $6.2K | -77.1% |
| 2010 | $26.9K | +141.4% |
| 2009 | $11.1K | — |
| 2007 | $0.00 | — |
| 2007 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $95.29M | +92.6% | +16.3% |
| June 30, 2025 | $81.95M | +81.4% | +59.8% |
| March 31, 2025 | $51.27M | +23.5% | -77.2% |
| December 31, 2024 | $224.46M | +501.5% | +353.6% |
| September 30, 2024 | $49.48M | +72.2% | +9.5% |
| June 30, 2024 | $45.18M | -8.0% | +8.9% |
| March 31, 2024 | $41.51M | +53.4% | +11.2% |
| December 31, 2023 | $37.32M | -28.0% | +29.8% |
- Kura Oncology, Inc. showed a decrease of -33.6% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Kura Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: